SCHEMBL10201426

SCHEMBL10201426

COC(=O)N[C@](C#C[Si](C)(C)C)(CN1Cc2ccc(OC)c(F)c2C1=O)C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TNF P01375 15/20 0.42
ADAM17 P78536 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10131261 0.87 TNF (0.48) TNFADAM17
SCHEMBL10200167 0.87 TNF (0.48) TNFADAM17
SCHEMBL14980183 0.85 ADAM17 (0.30) ADAM17
SCHEMBL14980155 0.85 ADAM17 (0.30) ADAM17
SCHEMBL10263492 0.84 TNF (0.44) TNFADAM17
SCHEMBL10201424 0.82 LRRK2 (0.36) TNF
SCHEMBL10112043 0.79 TNF (0.50) TNF
SCHEMBL13895587 0.79 ADAM17 (0.34) TNFADAM17
SCHEMBL14978276 0.76
SCHEMBL14978282 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 TNF 1/4885ADAM17 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.